Analysis of Electrical Brain Waves in Neurotoxicology: Gamma-Hydroxybutyrate by Binienda, Z.K et al.
236 Current  Neuropharmacology, 2011, 9, 236-239   
  1570-159X/11 $58.00+.00  ©2011 Bentham Science Publishers Ltd. 
Analysis of Electrical Brain Waves in Neurotoxicology: Gamma-
Hydroxybutyrate 
Z.K. Binienda
1,*, M.A. Beaudoin
2, B.T. Thorn
3 and S.F. Ali
1 
1Division of Neurotoxicology; 
2Z-Tech, Co.; 
3Division of Personalized Nutrition and Medicine; FDA/NCTR, Jefferson, 
AR, USA 
Abstract: Advances in computer technology have allowed quantification of the electroencephalogram (EEG) and expan-
sion of quantitative EEG (qEEG) analysis in neurophysiology, as well as clinical neurology, with great success. Among 
the variety of techniques in this field, frequency (spectral) analysis using Fast Fourier Transforms (FFT) provides a sensi-
tive tool for time-course studies of different compounds acting on particular neurotransmitter systems. Studies presented 
here include Electrocorticogram (ECoG) analysis following exposure to a glutamic acid analogue - domoic acid (DOM), 
psychoactive indole alkaloid - ibogaine, as well as cocaine and gamma-hydroxybutyrate (GHB). The ECoG was recorded 
in conscious rats via a tether and swivel system. The EEG signal frequency analysis revealed an association between 
slow-wave EEG activity delta and theta and the type of behavioral seizures following DOM administration. Analyses of 
power spectra obtained in rats exposed to cocaine alone or after pretreatment with ibogaine indicated the contribution of 
the serotonergic system in ibogaine mediated response to cocaine (increased power in alpha1 band). Ibogaine also lowered 
the threshold for cocaine-induced electrographic seizures (increased power in the low-frequency bands, delta and theta). 
Daily intraperitoneal administration of cocaine for two weeks was associated with a reduction in slow-wave ECoG activ-
ity 24 hrs following the last injection when compared with controls. Similar decreased cortical activity in low-frequency 
bands observed in chronic cocaine users has been associated with reduced metabolic activity in the frontal cortex. The 
FFT analyses of power spectra relative to baseline indicated a significant energy increase over all except beta2 frequency 
bands following exposure to 400 and 800 mg/kg GHB. The EEG alterations detected in rats following exposure to GHB 
resemble absence seizures observed in human petit mal epilepsy. Spectral analysis of the EEG signals combined with be-
havioral observations may prove to be a useful approach in studying chronic exposure to drugs of abuse and treatment of 
drug dependence. 
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INTRODUCTION 
  Electroencephalography and neuroimaging are major 
techniques in brain investigation. Electrocerebral activity 
represents local action potentials and widespread excitatory 
and inhibitory postsynaptic potentials recorded as the EEG. 
ECoG records an average of synchronous, widespread post-
synaptic potentials arising in vertically oriented pyramidal 
cells of the upper layers of the cerebral cortex [1]. Advances 
in computer technology have allowed quantification of the 
EEG and expansion of quantitative EEG (qEEG) analysis in 
neurophysiology, as well as clinical neurology, with a great 
success. Among the variety of techniques in this field, the 
computer assisted frequency (spectral) analysis (FFT) of the 
EEG signals provides a sensitive tool for time-course studies 
of different compounds acting on particular neurotransmitter 
systems. Frequency data are often analyzed as the power 
spectrum, measured as total power in microvolts-squared 
divided by frequency (V
2/Hz) and separated into low (delta, 
theta) or high (alpha, beta) frequency bands. 
ANIMALS, INSTRUMENTATION, DATA ANALYSIS 
  Adult, male Sprague-Dawley rats of the Charles River 
cesarean delivered (CD) strain were used in the study. 
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Animals were kept under controlled environmental condi-
tions (temperature 22
oC, relative humidity 45-55%, 12-h 
light/dark cycle) and housed individually with NIH-41 Irra-
diated Rodent Diet (Harlan Teklad, Madison, WI) chow and 
tap water supplied ad libitum. Bipolar stainless steel elec-
trodes were implanted 3 mm laterally from the sagittal fis-
sure, 1 and 4 mm posterior to the bregma. They were refer-
enced to a ground electrode placed in the dorsal neck. The 
ECoG was recorded via a tether and swivel system at least 
one week after implantation. During recording, the animals 
remained in a microdialysis bowl placed inside a Faraday 
cage. Amplified signals were rectified to pass frequencies of 
1-40 Hz and processed with Lab View software (National 
Instruments, Austin, TX). The power spectra obtained by use 
of FFT were divided into 1.25-4.5 Hz (delta), 4.75—6.75 
(theta), 7.00-9.50 Hz (alpha1), 9.75-12.50 Hz (alpha2), 12.75-
18.5 Hz (beta1), and 18.75-35.00 Hz (beta2) frequency bands 
[2]. Following the intraperitoneal (i.p.) saline injection and 
30-min baseline recording, rats were treated i.p. with com-
pounds of interest and recording continued for the next 60 -
120 min. 
  All animal procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) of the NCTR and 
conducted in full accordance with the PHS policy on humane 
care and use of laboratory animals and the NIH guide for the 
care and use of laboratory animals. Analysis of Electrical Brain Waves In Neurotoxicology  Current Neuropharmacology, 2011, Vol. 9, No. 1    237 
  In order to analyze data statistically, each power meas-
urement during treatment was divided by the median power 
in the reference run (baseline) in order to place all animals 
on the same scale despite factors that made the absolute 
power different between animals. Data were subsequently 
normalized using a log transformation. Power difference 
between a 5-min interval and the baseline level 30-min pe-
riod was tested against zero using the Student’s t-test. Values 
of p < 0.05 were considered statistically significant. 
DOMOIC ACID (DOM) STUDY 
  DOM, a contaminant of some seafood was identified as 
the culprit in mussel poisoning. Intoxication was marked by 
neurological symptoms including seizures and behavioral 
symptoms. An increase in the release of glutamate and a 
decrease of the release of GABA are consistent with excito-
toxic mechanism of DOM toxicity [3]. Results of the brain 
wave analysis demonstrated that FFT can simplify the con-
version of raw EEG signals into a numerically useful form. 
An FFT analysis of the ECoG recorded from rats before and 
after i.p. dosing with DOM revealed high voltage activity 
(electrographic seizures) not accompanied initially by any 
behavioral seizures. The high dose (4.4 mg/kg) DOM group 
ECoG was elevated beginning 30 min postinjection, whereas 
in the low dose (2.2 mg/kg) group became elevated only 
after 110 min (Fig. (1)). Further division of the ECoG data 
into frequency bands indicated that the initial power increase 
was mainly at the lower frequencies delta and theta. Statisti-
cally significant elevations in delta and theta waves were 
observed both sooner and at a lower dose than size-related 
behaviors [4]. 
IBOGAINE AND COCAINE STUDIES  
  A psychoactive indole alkaloid, ibogaine, has been 
evaluated in several laboratories for its properties as an anti-
addictive drug. However in animal studies, exposure to 
ibogaine has been associated with neurotoxic side effects. In 
our study, spectral analysis of the ECoG in rats injected with 
cocaine HCl alone (20 mg/kg, i.p. ), or pretreated with 
ibogaine (50 mg/kg), followed one hour later by cocaine, 
revealed that administration of cocaine alone was associated 
only with a significant power increase in the alpha1 fre-
quency band during the first 30 min postinjection. The alpha1 
increase was maintained throughout recording when cocaine 
was injected after ibogaine pretreatment. The spectral pattern 
obtained after ibogaine/cocaine treatment showed increased 
power in the low frequency bands and enhancement of 
power in the alpha1 band, indicating the contribution of the 
serotonergic system in the ibogaine-mediated response to 
cocaine. The enhancement of power observed in low fre-
quency bands after the combined treatment with ibogaine/ 
cocaine suggests that ibogaine at high doses decreases the 
threshold for cocaine-induced seizures [5]. 
  The FFT analysis of ECoG recorded in rats injected with 
15 mg/kg cocaine HCl i.p. for two weeks revealed a signifi-
cant decrease in slow-wave frequency bands (delta, theta). 
Data were consistent with reported findings in cocaine-
dependent human subjects where repeated exposure to co-
caine resulted in a decrease in slow-wave brain activity 
showing usefulness of the animal model developed in our lab 
in the study of human cocaine dependence [6]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). (a-c) Plots of the voltage as a function of time for the 
ECoG trace taken from the stripchart of a rat injected with DOM at 
4.4 mg/kg. Baseline period (a), initial bursts of activity (b), in-
creased rate of high frequency, high voltage ECoG bursts, and a 
lower voltage, lower frequency interictal spikes. (d) FFT of the 1-
40 Hz frequency spectrum of rats injected with DOM at 2.2 mg/kg 
and 4.4 mg/kg. Power values were calculated as percent of the 30-
min baseline power recorded after saline injection (assigned as 
value of 100% in each band). Experimental time in 15 min intervals 
is denoted on the X-axis.  
Mean ± SEM. n=5. *p<0.05 significantly different from baseline. 
GHB STUDY 
  GHB, a short chain fatty acid and a GABA derivative, 
has been characterized as an inhibitory neurotransmitter in 
the brain and neuromodulator of the dopaminergic, opioid 
and GABA-ergic neurotransmitter systems [7, 8]. While ap-
proved by the US FDA for the treatment of narcolepsy, the 
abuse of GHB as a psychotropic drug became a world-wide 
problem by the late 90’s. Known to recreational users as G, 
gib, soap, salty water or nitro, exposure to GHB induces 
short term amnesia, increases libido and euphoria. The disin-
hibition of sexual behavior produced by GHB has also given 
it the moniker of a date-rape drug because of its abuse in 
sexual assaults. 
  Quantitative autoradiography and imaging techniques 
have allowed the detection of high-affinity GHB receptor 
sites, particularly dense in the neuronal cells of forebrain 
region such as the striatum - including the nucleus accum-
bens, hippocampus, and thalamus [9]. A cloning technique 
allowed identification of a GHB specific receptor that has 
been postulated to exist in the sites matching the regions of 
GABAB. [10]. The interaction with GABAB receptors leads 
to an inhibition in dopamine (DA) release and alters of the 
EEG profiles, as well as behavioral effects such as sedation, 
and decreases motor activity [11]. 
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  As was expected due to the ability of GHB to block the 
firing of DA neurons, microdialysis sampling revealed that 
acute GHB administration in awake rats leads to a decrease 
in striatal DA compared with baseline levels [12, 13]. In 
turn, the pharmacokinetic/pharmacodynamic model allowed 
detection of an IC50 increase in the GHB inhibition of the DA 
synthesis rate following chronic exposure to GHB, indicating 
decreased DA sensitivity toward the GHB inhibitory action 
[13]. 
  The effect of GHB on electroencephalographic signals 
has been investigated in animal models and human [14-18]. 
While acute exposure to exogenous GHB in rats at low doses 
(50-100 mg/kg) induced immobility and sleep, a hypersyn-
chronous electrographic seizures resembling generalized 
nonconvulsive epilepsy were observed following GHB at 
doses higher than 200 mg/kg [15]. These EEG changes were 
blocked by GABAB receptor antagonists [16]. Chronic expo-
sure to GHB in the rat led to a reduced sleep period reflected 
by the EEG, and indicated end-organ sensitivity, i.e., toler-
ance to the hypnotic action of GHB [19]. 
  In our study, following a saline injection and 30 min re-
cording of baseline ECoG, rats were treated i.p. with GHB at 
100, 200, 400, and 800 mg/kg and recording continued for 
the next 60 min. The real-time ECoG recording indicated a 
dose response in bilateral spike-and-wave discharges consis-
tent with electrographic seizures. These 5-7 sec spikes, ini-
tially observed within 7-10 min following 200 mg/kg GHB, 
were accompanied by a desynchronized ECoG, remaining 
progressively longer and lasting throughout the 60-min re-
cording period in 400 and 800 mg/kg GHB treated rats. The 
alterations in ECoG activity were associated with behavioral 
sedation (“freezing”) characterized by immobility and   
staring. The FFT analyses of power spectra relative to base-
line indicated a significant energy increase over all, except 
beta2, frequency bands following 400 and 800 mg/kg GHB 
(Fig. (2)). The significant power increases after 400 mg/kg 
GHB were observed within approximately 30 min compared 
to 10-15 min after 800 mg/kg. The EEG alterations detected 
in rats following exposure to GHB resemble absence   
seizures observed in human petit mal epilepsy. 
CONCLUSIONS 
  The FFT mathematical conversion applied to EEG sig-
nals takes into account both frequency and amplitude of the 
signal within defined powers (frequency bands). The fre-
quency analysis revealed differences between a particular 
class of drugs allowing “fingerprinting” of hallucinogenic 
and non-hallucinogenic amphetamine derivatives. While an 
increase in alpha1 power correlating with a serotonin in-
crease were observed in hallucinogenic actions, the spectral 
patterns following exposure to non-hallucinogens were char-
acterized by a decrease in the alpha2 and delta band [2].  
  Spectral analysis applied in our studies allowed associa-
tion of low frequency power bands delta and theta activity 
with the early development of convulsant activity within the 
limbic system following exposure to DOM. The EEG events 
preceded motoric seizures. The FFT –processed ECoG suc-
cessfully measured increases in delta and theta that were 
below the threshold of voltage or duration required to induce 
seizure-related behaviors. The enhancement of spectral 
power observed in low frequency bands after the ibogaine/ 
cocaine treatment indicating lower threshold for seizures   
was somehow contradictory to the noncompetitive NMDA 
receptor antagonist properties of ibogaine. However, 
ibogaine, like another NMDA antagonist, MK-801, stimu-
lates corticosterone release that has been shown to increase 
susceptibility to seizures. 
  The ECoG findings of a deficit in slow-wave brain activ-
ity after repeated exposure to cocaine confirmed observa-
tions in human subjects where addiction to cocaine was as-
sociated with deficits in delta power combined with reduced 
blood flow in the prefrontal cortex [20]. Our whole animal 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Effects produced by gamma-hydroxybutyrate injections at 100, 200, 400, and 800 mg/kg, i.p. on cortical EEG (ECoG) power spec-
tra. Relative values calculated as percent of the 30-min baseline power assumed 100% in each band. Mean ± SEM. 
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experimental approach may be useful in the study of drug 
dependence. The in vivo encephalography animal model of-
fers opportunity to assess the baseline activity in the cortical 
areas before exposures to drugs of addiction occur. A similar 
approach would not be permitted in human subjects for ethi-
cal and legal reasons.  
  This experimental setting presents a similar advantage in 
the study of GHB addiction. Analysis of spectral patterns 
obtained in this study provide a sensitive tool to investigate 
GHB interaction with neurotransmitters in the study of GHB 
addiction. Additionally, the EEG profiles obtained in the 
GHB experiment with behavioral effects showed similarity 
with absence epilepsy induced by GHB and induced by 
GABA agonists as reported earlier [21].  
  In summary, spectral analysis of the EEG signals com-
bined with behavioral observations may prove to be a useful 
approach in studying chronic exposure to drugs of abuse and 
treatment of drug dependence.  
DISCLAIMER 
  This document has been reviewed in accordance with 
United States Food and Drug Administration (FDA) policy 
and approved for publication. Approval does not signify that 
the contents necessarily reflect the position or opinions of the 
FDA nor does mention of trade names or commercial prod-
ucts constitute endorsement or recommendation for use. The 
findings and conclusions in this report are those of the 
authors and do not necessarily represent the views of the 
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